何玉先課題組
各實驗室介紹
課題組成員：
何玉先 博士，長(cháng)聘教授、研究員、博士生導師
種輝輝 博士、研究員、碩士生導師
李 悄 博士、主管技(jì )師
朱園美 碩士、主管技(jì )師
研究方向
本課題主要從事艾滋病的分(fēn)子病毒學(xué)和免疫學(xué)研究，課題内容聚焦三個方面:
(1) HIV感染膜融合機制研究；
(2) HIV基因治療新(xīn)策略研究；
(3) 廣譜抗病毒藥物(wù)的研發。
代表性論文(wén)
(1) Jing Xue; Huihui Chong; Yuanmei Zhu; Jingjing Zhang; Ling Tong; Jiahan Lu; Ting Chen; Zhe Cong; Qiang Wei; Yuxian He. Efficient treatment and pre-exposure prophylaxis in rhesus macaques by an HIV fusion-inhibitory lipopeptide. Cell, 2022, 185(1): 131-144
(2) Yue Chen; Hongliang Jin; Xiaoran Tang; Li Li; Xiuzhu Geng; Yuanmei Zhu; Huihui Chong; Yuxian He. Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targ eting the gp41 fusion protein: new strategies for HIV gene therapy. Emerg Microbes Infect, 2022, 11(1): 30-49
(3) Hongliang Jin; Xiaoran Tang; Li Li; Yue Chen; Yuanmei Zhu; Huihui Chong; Yuxian He. Generation of HIV-resistant cells with a single-domain antibody: implications for HIV-1 gene therapy. Cell Mol Immunol, 2021, 18(3): 660-674
(4) Yuanmei Zhu; Danwei Yu; Yang Han; Hongxia Yan; Huihui Chong; Lili Ren; Jianwei Wang; Tais heng Li; Yuxian He. Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recover ed SARS patients and immunized animals. Sci Adv, 2020, 6(45): eabc9999.
(5) Huihui Chong; Jing Xue; Yuanmei Zhu; Zhe Cong; Ting Chen; Qiang Wei; Chuan Qin; Yuxian He. Monotherapy with a low-dose lipopeptide HIV fusion inhibitor maintains long-term viral suppress ion in rhesus macaques. PLoS Pathog, 2019, 15(2): e1007552
成果轉化
(1) 國(guó)家1類抗HIV新(xīn)藥利普韋肽進入II期臨床試驗；
(2) 國(guó)家1類抗HIV新(xīn)藥注射LP-98進入I期臨床試驗；
(3) 國(guó)家1類抗SARS-CoV-2新(xīn)藥YYYK017進入II/III期臨床試驗；
(4) 廣譜抗病毒藥物(wù)IPBZS01實現成果轉化并開展Pre-IND研究。